A recent study presented at the American Academy of Neurology annual meeting highlights significant disparities in the diagnosis of generalized myasthenia gravis (gMG) among minority patients. Dr. Marla Black Morgan, a neurologist with Phoebe Neurology Associates, spearheaded the investigation, revealing that racial and ethnic minority patients often experience longer diagnostic journeys compared to their white counterparts.
The study, part of Project ASPI
RE, examined the diagnostic experiences of patients with gMG, a rare neuromuscular disease. Findings indicate that minority patients face numerous barriers, including limited access to healthcare, socioeconomic challenges, and potential biases within the medical system. These obstacles contribute to delays in diagnosis and treatment, exacerbating health disparities.
Dr. Morgan’s research involved querying both patients and healthcare providers to understand the perceived barriers to timely diagnosis. The study found that minority patients were less likely to be recruited into clinical trials, further limiting their access to cutting-edge treatments. Additionally, factors such as insurance coverage and geographic location played a role in the disparities observed.
The impact of these delays is profound, leading to prolonged suffering and potentially worse health outcomes for minority patients. Dr. Morgan emphasizes the need for targeted interventions to address these disparities, including improving healthcare access and increasing awareness among providers. By tackling these issues, the medical community can work towards ensuring equitable care for all patients with gMG.
See: “Delays, Disparities in gMG Diagnosis Among Minority Patients” (April 15, 2025)
